Mark Thomas Deming

Mark Thomas Deming — Patent Litigation Practice Summary

Specialty / focus areas. Deming is an intellectual-property litigator and shareholder at Polsinelli PC (Chicago), with a practice centered on pharmaceutical and medical-device patent litigation, particularly Hatch-Waxman/Paragraph IV ANDA disputes, where he represents both brand and generic companies. He also handles trademark and trade dress matters. His technical background is in computer engineering, and he has litigated electronics/software patents as well — most notably touch-input and interactive-display patents for Power2B against Samsung. Sources: The Knowledge Group speaker profile; Bloomberg Law (2021); BioSpace.

Side preference. The tracked appearance data shows one defendant-side matter (Power2B Inc. as patent owner/respondent), but the verifiable record shows Deming works both sides. He has prosecuted ANDA infringement actions as plaintiffs' counsel for Melinta/CorMedix and defended generic petitioners in IPR proceedings (e.g., backup counsel for petitioner Padagis in Padagis v. Neurelis, IPR2025-00464). He is described as representing both brand and generic pharmaceutical companies.

Firm context. Deming is a shareholder in Polsinelli's Hatch-Waxman litigation group. Before joining Polsinelli, he clerked two years for Judge Michael Schneider and Magistrate Judge John Love in the Eastern District of Texas, gaining trial, Markman, and discovery experience on one of the busiest patent dockets.

Notable cases / outcomes. His most prominent tracked matter is the Power2B v. Samsung Electronics IPR appeal (Fed. Cir. Nos. 23-1629, 23-1630, 23-2184, decided 2025), where the Federal Circuit split the outcome — affirming some PTAB validity rulings, reversing the Board's "detector assembly" claim construction, and remanding. In Melinta Therapeutics v. Nexus Pharmaceuticals (N.D. Ill.), he represented the Minocin® minocycline patent owners in ANDA litigation that produced a four-day bench-trial win and permanent injunction, affirmed by the Federal Circuit in June 2026. He is also counsel in the pending Melinta v. Gland Pharma ANDA suit (N.D. Ill., filed 2025).

PTAB / IPR experience. Yes — he represented Power2B as patent owner across five Samsung IPRs (IPR2021-01190, -01220, -01239, -01257, -01266) and their Federal Circuit appeals, and has served as petitioner-side backup counsel in IPRs (Padagis v. Neurelis).

Bar / education. B.S. Computer Engineering, University of Illinois (2006); J.D., University of Illinois (2009). Admitted: Illinois (2010), E.D. Tex. (2011), USPTO (Reg. No. 69,263, 2012), N.D. Ill. (2012), Federal Circuit (2013). Recognized in Best Lawyers in America for Litigation – Intellectual Property since 2023.